Skip Navigation
Find a Doctor


Photo of Dr. Ie-Ming Shih, MD PhD

Ie-Ming Shih, MD PhD

Professor of Gynecology and Obstetrics
Appointment Phone


Main Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Professor of Gynecology and Obstetrics
  • Professor of Oncology
  • Professor of Pathology

Centers & Institutes

  • Ovarian Cancer Center


Gynecologic/Obstetric Pathology, Pathology

Research Interests

Cancer Pathogenesis; Cancer Diagnostics; Molecular Cancer Therapy


1988, MD, Taipei Medical University, Taiwan
1993, PhD, University of Pennsylvania, PA
1994-1997 Resident, Department of Pathology, Johns Hopkins Hospital
1997-1998 Clinical Fellow in Gynecologic Pathology (with Dr. Kurman), Johns Hopkins Hospital
1998-2000 Research Fellow, Johns Hopkins Oncology Center (with Dr. Vogelstein), Baltimore 2000-2001 Instructor, Department of Pathology, Johns Hopkins Medical Institution, Baltimore
2001-2003 Assistant Professor, Department of Pathology, Johns Hopkins Medical Institution,
2003-2008 Associate Professor, Departments of Pathology, Oncology, Gynecology/Obstetrics,
2008- Professor, Departments of Pathology, Oncology, Gynecology/Obstetrics, Johns Hopkins Medical Institution, Baltimore


  • English
  • Chinese
  • Taiwanese


American Association for Cancer Research
United States and Canadian Association of Pathologists

Additional Resources

Additional Resources +
  • Education +


    • University of Pennsylvania Health System School of Medicine (Philadelphia PA) (1993)
    • Taipei Medical University (Taipei ) (1988)


    • Johns Hopkins University School of Medicine / Pathology (Baltimore MD) (1997)
    • Taipei Medical University / Anatomic Pathology (Taipei ) (1989)


    • Johns Hopkins University School of Medicine / Pathology (Baltimore MD) (2000)
    • The Wistar Institute / Pathology (Philadelphia PA) (1994)


    • American Board of Pathology / Anatomic Pathology (1997)
  • Research & Publications +

    Selected Publications

    Research Summary

    Dr. Shih's research team focuses on the molecular pathology of ovarian cancer, the most lethal malignant tumor among gynecological neoplasms. The long-term objectives of his research team are:

    A. to understand the molecular etiology in the development of human cancer, and
    B. to identify and characterize cancer molecules for cancer detection, diagnosis, and therapy.

    Dr. Shihs team use ovarian carcinoma as a disease model because it is one of the most aggressive neoplastic diseases in women. For the first research direction, they aim to identify and characterize the molecular alterations during initiation and progression of ovarian carcinomas. Previous genome-wide analyses from his team have identified molecular alterations in several new cancer-associated genes including Rsf-1, NAC1, and fatty acid synthase among several others. The investigators have demonstrated the essential roles of these gene products in sustaining tumor growth and survival. Current projects are focusing on elucidating the mechanisms by which these genes function in cancer cells and delineating the cross-talks between those genes and other signaling pathways.
    Specifically, they are identifying their downstream targets and pathways, and are determining their roles in maintaining cancer stem cell-like features, invasion and drug resistance. The second research direction is a translation-based study. The team is assessing the clinical significance of an array of new cancer-associated genes in predicting clinical outcome and in the developing potential target-based therapy in mouse preclinical models.

    They are also establishing innovative assays for cancer detection and diagnosis by identifying new tumor-associated genetic and protein biomarkers through serial analysis of gene expression, gene expression arrays, proteomics and methylation profiling. The purpose is to develop new tools in detecting human cancer using body fluid samples. In collaboration with several investigators, they are integrating new technologic platforms such as microfluidics, nanotechnology and systems biology in their studies. More details of Dr.Shihs research can be found at

    Journal Citations

    Bazzaro, M.; Lee, M.K.; Zoso, A.; Stirling, W.L.; Santillan, A.; Shih Ie, M.; Roden, R.B. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006 Apr 1;66(7):3754-3763.

    Mao, T.L.; Hsu, C.Y.; Yen, M.J.; Gilks, B.; Sheu, J.J.; Gabrielson, E.; Vang, R.; Cope, L.; Kurman, R.J.; Wang, T.L.; Shih Ie, M. Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol. 2006 Sep;37(9):1169-1175.

    Nakayama, K.; Nakayama, N.; Davidson, B.; Katabuchi, H.; Kurman, R.J.; Velculescu, V.E.; Shih Ie, M.; Wang, T.L. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther. 2006 Jun;5(6):630-634.

    Nakayama, K.; Nakayama, N.; Kurman, R.J.; Cope, L.; Pohl, G.; Samuels, Y.; Velculescu, V.E.; Wang, T.L.; Shih Ie, M. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006 Jul;5(7):779-785.

    Park, J.T.; Li, M.; Nakayama, K.; Mao, T.L.; Davidson, B.; Zhang, Z.; Kurman, R.J.; Eberhart, C.G.; Shih Ie, M.; Wang, T.L. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006 Jun 15;66(12):6312-6318.

    Kurman, R.J.; Visvanathan, K.; Roden, R.; Wu, T.C.; Shih Ie, M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008 Apr;198(4):351-356.

    Sturgeon, C.M.; Duffy, M.J.; Stenman, U.H.; Lilja, H.; Brunner, N.; Chan, D.W.; Babaian, R.; Bast, R.C., Jr.; Dowell, B.; Esteva, F.J.; Haglund, C.; Harbeck, N.; Hayes, D.F.; Holten-Andersen, M.; Klee, G.G.; Lamerz, R.; Looijenga, L.H.; Molina, R.; Nielsen, H.J.; Rittenhouse, H.; Semjonow, A.; Shih Ie, M.; Sibley, P.; Soletormos, G.; Stephan, C.; Sokoll, L.; Hoffman, B.R.; Diamandis, E.P. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec;54(12):e11-79.

    Kuo, K.T.; Mao, T.L.; Jones, S.; Veras, E.; Ayhan, A.; Wang, T.L.; Glas, R.; Slamon, D.; Velculescu, V.E.; Kuman, R.J.; Shih Ie, M. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009 May;174(5):1597-1601.

    Lotan, T.L.; Ye, H.; Melamed, J.; Wu, X.R.; Shih Ie, M.; Epstein, J.I. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009 Jul;33(7):1037-1041.

    Tsai-Turton, M.; Santillan, A.; Lu, D.; Bristow, R.E.; Chan, K.C.; Shih Ie, M.; Roden, R.B. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009 Jul;114(1):12-17.

    Chen, X.; Stoeck, A.; Lee, S.J.; Shih, I.M.; Wang, M.M.; Wang, T.L. Jagged1 expression regulated by Notch3 and Wnt/beta-catenin signaling pathways in ovarian cancer. Oncotarget. 2010 Jul;1(3):210-218.

    Elliott, K.S.; Zeggini, E.; McCarthy, M.I.; Gudmundsson, J.; Sulem, P.; Stacey, S.N.; Thorlacius, S.; Amundadottir, L.; Gronberg, H.; Xu, J.; Gaborieau, V.; Eeles, R.A.; Neal, D.E.; Donovan, J.L.; Hamdy, F.C.; Muir, K.; Hwang, S.J.; Spitz, M.R.; Zanke, B.; Carvajal-Carmona, L.; Brown, K.M.; Hayward, N.K.; Macgregor, S.; Tomlinson, I.P.; Lemire, M.; Amos, C.I.; Murabito, J.M.; Isaacs, W.B.; Easton, D.F.; Brennan, P.; Barkardottir, R.B.; Gudbjartsson, D.F.; Rafnar, T.; Hunter, D.J.; Chanock, S.J.; Stefansson, K.; Ioannidis, J.P. Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS One. 2010;5(5):e10858.

    Gross, A.L.; Kurman, R.J.; Vang, R.; Shih Ie, M.; Visvanathan, K. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol. 2010;2010:126295.

    Hong, S.K.; Chaturvedi, R.; Piazuelo, M.B.; Coburn, L.A.; Williams, C.S.; Delgado, A.G.; Casero, R.A., Jr.; Schwartz, D.A.; Wilson, K.T. Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity. Inflamm Bowel Dis. 2010 Sep;16(9):1557-1566.

    Jinawath, N.; Vasoontara, C.; Jinawath, A.; Fang, X.; Zhao, K.; Yap, K.L.; Guo, T.; Lee, C.S.; Wang, W.; Balgley, B.M.; Davidson, B.; Wang, T.L.; Shih Ie, M. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One. 2010;5(6):e11198.

    Jones, S.; Wang, T.L.; Shih Ie, M.; Mao, T.L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A., Jr.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E.; Papadopoulos, N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010 Oct 8;330(6001):228-231

    Kuo, K.T.; Mao, T.L.; Chen, X.; Feng, Y.; Nakayama, K.; Wang, Y.; Glas, R.; Ma, M.J.; Kurman, R.J.; Shih Ie, M.; Wang, T.L. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 2010 Apr 1;16(7):1997-2008.

    Liu, K.J.; Brock, M.V.; Shih Ie, M.; Wang, T.H. Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J Am Chem Soc. 2010 Apr 28;132(16):5793-5798

    Park, J.T.; Chen, X.; Trope, C.G.; Davidson, B.; Shih Ie, M.; Wang, T.L. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010 Sep;177(3):1087-1094.

    Satoh, H.; Moriguchi, T.; Taguchi, K.; Takai, J.; Maher, J.M.; Suzuki, T.; Winnard, P.T., Jr.; Raman, V.; Ebina, M.; Nukiwa, T.; Yamamoto, M. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis. 2010 Oct;31(10):1833-1843.

    Sheu, J.J.; Guan, B.; Choi, J.H.; Lin, A.; Lee, C.H.; Hsiao, Y.T.; Wang, T.L.; Tsai, F.J.; Shih Ie, M. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 2010 Dec 3;285(49):38260-38269.

    Shih Ie, M.; Chen, L.; Wang, C.C.; Gu, J.; Davidson, B.; Cope, L.; Kurman, R.J.; Xuan, J.; Wang, T.L. Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol. 2010 Dec;203(6):584 e581-522.

    Ueda, S.M.; Yap, K.L.; Davidson, B.; Tian, Y.; Murthy, V.; Wang, T.L.; Visvanathan, K.; Kuhajda, F.P.; Bristow, R.E.; Zhang, H.; Shih Ie, M. Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol. 2010;2010:285191.

    Davidson, B.; Stavnes, H.T.; Holth, A.; Chen, X.; Yang, Y.; Shih, I.M.; Wang, T.L. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 2010 Jan 30.

    Shih, I.M.; Nakayama, K.; Wu, G.; Nakayama, N.; Zhang, J.; Wang, T.L. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol. 2011 Jan 14;Epub 1/14/11.
  • Academic Affiliations & Courses +
  • Activities & Honors +


    2RO1 CA103937 12/01/2004 -11/30/2012
    Molecular diagnostics for malignant effusion

    1RO1 CA129080 4/01/2008 - 01/31/2013
    The Roles of HBXAP Gene in Ovarian Cancer

    1RO1 CA116184 04/01/2007 - 03/30/2011
    Pathogenesis of ovarian serous borderline tumors

    OC080469 07/01/2009 - 06/30/2010
    Department of Defense, Ovarian Cancer Research Program
    Consortium Planning Award

    1R21CA120742 04/01/2008 - 03/31/2010
    Nanobiosensing Method for Point Mutation Detection of Cancer

    GMC-113937 07/01/2008 - 06/30/2012
    American Cancer Society
    Notch3 Signaling Pathway in the Ovarian Carcinoma

    Professional Activities

    NCI/NIH, Member of Cancer Molecular Pathobiology Study Section (CAMP), 2006 -2011
    NCI/NIH, Member of Onc-L (12)B Cancer Diagnostic & Treatment Study Section, 2005-2007
    NCI/NIH, Ad Hoc member, IMAT (R21/R33) New innovative technology in cancer, 2002
    NCI/NIH, Site visit adviser, Early Detection Network (EDRN), Cancer Biomarkers Research Group, 2008
    US DoD ovarian cancer research program, 2005, 2006, 2009
  • Videos & Media +
  • Events +
  • Contact & Locations +


    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Hospital Main Entrance - Sheikh Zayed Tower
    Baltimore, MD 21287
    Phone: 410-502-7774
    Appointment Phone: 410-502-7774
    Location Map


    • Pathology

Is This You? Edit Profile


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.